BioCryst Pharmaceuticals, Inc. (BCRX) Reports In-Line Q4 EPS
Tweet
Share
E-mailGet Alerts BCRX Hot Sheet
Price: $8.70 +2.35%
Revenue Growth %: +13.7%
Financial Fact:
Interest expense: -1.47M
Today's EPS Names:
PLCE, COE, JVA, More
Revenue Growth %: +13.7%
Financial Fact:
Interest expense: -1.47M
Today's EPS Names:
PLCE, COE, JVA, More
Join SI Premium – FREE
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) reported Q4 EPS of ($0.29), in-line with the analyst estimate of ($0.29). Revenue for the quarter came in at $5.2 million versus the consensus estimate of $7.34 million.
BioCryst Pharmaceuticals, Inc. sees FY2012 EPS of (n/a). BioCryst Pharmaceuticals, Inc. sees FY2012 revenue of $5 million.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
BioCryst Pharmaceuticals, Inc. sees FY2012 EPS of (n/a). BioCryst Pharmaceuticals, Inc. sees FY2012 revenue of $5 million.
For earnings history and earnings-related data on BioCryst Pharmaceuticals, Inc. (BCRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Nvidia pitches Vera CPU to Chinese clients with August delivery target
- Investing.com’s stocks of the week
- Lennar Corp. (LEN) Misses Q2 EPS by 1c
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
